Ancora Advisors’s AbbVie ABBV Stock Holding History

Ancora Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$69.1M	Sell	317,574 -21,356	-6%	-$4.74M	1.47%	11
2025 Q4	$77.4M	Sell	338,930 -1,422	-0.4%	-$324K	1.6%	11
2025 Q3	$78.8M	Sell	340,352 -5,403	-2%	-$1.1M	1.57%	11
2025 Q2	$64.2M	Buy	345,755 +1,727	+0.5%	+$321K	1.33%	14
2025 Q1	$72.1M	Sell	344,028 -6,610	-2%	-$1.29M	1.61%	12
2024 Q4	$62.3M	Sell	350,638 -2,328	-0.7%	-$428K	1.39%	14
2024 Q3	$69.7M	Buy	352,966 +2,500	+0.7%	+$467K	1.59%	9
2024 Q2	$60.1M	Buy	350,466 +867	+0.2%	+$144K	1.49%	13
2024 Q1	$63.7M	Buy	349,599 +23,621	+7%	+$4.07M	1.45%	11
2023 Q4	$50.5M	Sell	325,978 -1,459	-0.4%	-$213K	1.19%	17
2023 Q3	$48.8M	Buy	327,437 +6,432	+2%	+$944K	1.3%	16
2023 Q2	$43.2M	Buy	321,005 +1,137	+0.4%	+$167K	1.14%	17
2023 Q1	$51M	Buy	319,868 +5,623	+2%	+$860K	1.45%	10
2022 Q4	$50.8M	Buy	314,245 +9,638	+3%	+$1.48M	1.46%	11
2022 Q3	$40.9M	Buy	304,607 +3,164	+1%	+$454K	1.26%	13
2022 Q2	$46.2M	Sell	301,443 -3,600	-1%	-$550K	1.3%	12
2022 Q1	$49.5M	Sell	305,043 -16,111	-5%	-$2.34M	1.2%	12
2021 Q4	$43.5M	Buy	321,154 +12,508	+4%	+$1.48M	1.03%	17
2021 Q3	$33.3M	Buy	308,646 +33,927	+12%	+$3.88M	0.86%	20
2021 Q2	$30.9M	Buy	274,719 +16,261	+6%	+$1.83M	0.81%	21
2021 Q1	$28M	Buy	258,458 +27,255	+12%	+$2.92M	0.77%	23
2020 Q4	$24.8M	Buy	231,203 +37,163	+19%	+$3.57M	0.8%	25
2020 Q3	$17M	Buy	194,040 +13,205	+7%	+$1.24M	0.67%	39
2020 Q2	$17.8M	Buy	180,835 +16,373	+10%	+$1.44M	0.74%	31
2020 Q1	$12.5M	Buy	164,462 +119,162	+263%	+$10.1M	0.58%	46
2019 Q4	$4.01M	Sell	45,300 -1,106	-2%	-$91.8K	0.15%	168
2019 Q3	$3.51M	Buy	46,406 +4,128	+10%	+$283K	0.15%	167
2019 Q2	$3.07M	Buy	42,278 +5,844	+16%	+$459K	0.14%	174
2019 Q1	$2.94M	Buy	36,434 +323	+0.9%	+$26.4K	0.13%	188
2018 Q4	$3.33M	Sell	36,111 -1,188	-3%	-$104K	0.16%	169
2018 Q3	$3.53M	Buy	37,299 +15	+0%	+$1.42K	0.14%	188
2018 Q2	$3.45M	Sell	37,284 -12,368	-25%	-$1.21M	0.15%	186
2018 Q1	$4.7M	Buy	49,652 +822	+2%	+$90.3K	0.21%	151
2017 Q4	$4.72M	Sell	48,830 -144	-0.3%	-$13.6K	0.25%	125
2017 Q3	$4.35M	Sell	48,974 -2,507	-5%	-$191K	0.25%	125
2017 Q2	$3.73M	Buy	51,481 +2,378	+5%	+$160K	0.24%	136
2017 Q1	$3.2M	Buy	49,103 +53	+0.1%	+$3.33K	0.22%	145
2016 Q4	$3.07M	Buy	49,050 +25,756	+111%	+$1.57M	0.22%	148
2016 Q3	$1.47M	Buy	23,294 +480	+2%	+$31.1K	0.15%	174
2016 Q2	$1.41M	Sell	22,814 -42,869	-65%	-$2.61M	0.16%	166
2016 Q1	$3.75M	Sell	65,683 -405	-0.6%	-$22.6K	0.46%	61
2015 Q4	$3.92M	Sell	66,088 -2,100	-3%	-$121K	0.5%	50
2015 Q3	$3.71M	Sell	68,188 -825	-1%	-$53.7K	0.48%	53
2015 Q2	$4.64M	Buy	+69,013	New	+$4.51M	0.54%	46
2015 Q1	–	Sell	-63,413	Closed	-$3.83M	–	48
2014 Q4	$4.15M	Sell	63,413 -4,655	-7%	-$293K	0.51%	53
2014 Q3	$3.93M	Sell	68,068 -7,650	-10%	-$425K	0.5%	50
2014 Q2	$4.27M	Sell	75,718 -363	-0.5%	-$19K	0.55%	42
2014 Q1	$3.91M	Buy	76,081 +4,300	+6%	+$217K	0.55%	49
2013 Q4	$3.79M	Buy	71,781 +4,250	+6%	+$209K	0.57%	44
2013 Q3	$3.02M	Buy	67,531 +50	+0.1%	+$2.22K	0.52%	49
2013 Q2	$2.79M	Buy	+67,481	New	+$2.95M	0.48%	50

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ancora Advisors's ABBV Position: Q1 2026 in Review

Ancora Advisors reduced its AbbVie (ABBV) stake by 6.3% in Q1 2026, selling an estimated $4.74M and leaving 317,574 shares worth $69.1M. The position accounts for 1.47% of the portfolio, ranked #11.

Ancora Advisors first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. The position peaked at $78.8M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Ancora Advisors held 317,574 shares of AbbVie worth $69.1M as of Q1 2026.
Ancora Advisors sold 21,356 AbbVie shares in Q1 2026, an estimated $4.74M.
AbbVie made up 1.47% of Ancora Advisors's portfolio in Q1 2026, its #11 holding.
Ancora Advisors first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
Ancora Advisors's AbbVie position peaked at $78.8M in Q3 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Ancora Advisors's 13F filing for Q1 2026, filed 15 May 2026.